|Table of Contents|

The clinical application of bone marrow smear and flow cytometry in the detection of minimal residues of neuroblastoma bone marrow metastasis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
870-875
Research Field:
Publishing date:

Info

Title:
The clinical application of bone marrow smear and flow cytometry in the detection of minimal residues of neuroblastoma bone marrow metastasis
Author(s):
HUANG Qianqian1; ZHANG Shuping2; SHEN Leyuan3; CHEN Yueqiong1; PENG Xiongwen1
1.Department of Hematology,Sun Yat-sen University Cancer Center,Guangdong Guangzhou 510060,China;2.Department of Laboratory Medicine,Peking University Shenzhen Hospital,Guangdong Shenzhen 518035,China;3.Department of Medical Examination Center,Sun Yat-sen
Keywords:
bone marrow smear; FCM; neuroblastoma; microlesion detection
PACS:
R739.4
DOI:
10.3969/j.issn.1672-4992.2022.05.023
Abstract:
Objective:To explore the clinical application value of bone marrow smear and flow cytometry(FCM) in the detection of minimal residual bone marrow in neuroblastoma（NB）.Methods:A retrospective analysis of 126 patients with neuroblastoma diagnosed pathologically in hospital from January 2019 to October 2020,collected patient clinical data,especially during the treatment period,bone marrow aspiration at the same site,bone marrow smear and flow cytometry detection.To analyze the clinical application value of two methods in the detection of small lesions in neuroblastoma bone marrow metastasis.Results:A total of 339 bone marrow smears and FCM samples were collected from 126 patients during this period time(the same patient was submitted for multiple examinations).There were 62 cases of neuroblastoma cells were detected in bone marrow smears,and 277 cases were without neuroblastoma cells,the positive rate was 18.29%,FCM indicated that there were 86 cells of non-hematopoietic system origin,the positive rate was 25.37%.Two methods had statistically significant differences in the detection rate of neuroblastoma bone marrow metastasis(P＜0.05).FCM-positive bone marrow smear negative group 34,accounting for 10.03%,10 parts by FCM negative smear-positive bone marrow,accounting for 2.95%.There were 52 cases in the double positive group of bone marrow smears and FCM,243 cases in the double negative group of bone marrow smears and FCM,and 96 cases in the positive group of bone marrow and/or FCM,the total positive rate was 28.32%.The coincidence rate of two methods in diagnosing the presence or absence of bone marrow metastasis in patients with neuroblastoma was 87.02%.The combined detection of two methods had a statistically significant difference in the positive detection rate of the bone marrow smear morphology single method(P＜0.05).There was no statistically significant difference in the positive detection rate between two methods of combined detection and FCM single method(P＞0.05).Conclusion:The coincidence rate of bone marrow smear and FCM detection in patients with neuroblastoma with or without bone marrow metastasis is as high as 87.02%.There are 96 positive samples of bone marrow and/or FCM,with a total positive rate of 28.32%.The combined detection of FCM and bone marrow smear improve the detection rate and accuracy of neuroblastoma bone marrow metastasis.It is recommended that both bone marrow smear and FCM micro-lesion detection be performed in clinic.

References:

[1] URAYAMA KY,VON BEHREN J,REYNOLDS P.Birth characteristics and risk of neuroblastoma in young children［J］.Am J Epidemiol,2007,165(5):486-495.
[2] BAO P,WU C,GU K,et al.Incidence trend of malignant tumors in children in Shanghai［J］.Chinese Journal of Epidemiology,2016,37(1):106-110.
[3] FAN HJ,HUANG C,SU Y,et al.Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children［J］.Chinese Journal of Pediatrics,2019,57(11):863-869.
[4] 亓凯,黎阳.神经母细胞瘤微小残留病检测的研究进展［J］.中国小儿血液与肿瘤杂志,2015,20(01):50-54. QI Kai,LI Yang.Research progress on detection of minimal residual disease in neuroblastoma［J］.Chinese Journal of Pediatric Hematology and Cancer,2015,20(01):50-54.
[5]王欢,高原,姜林林,等.儿童常见肿瘤骨髓转移的细胞形态学特点［J］.检验医学,2019,34(08):701-703. WANG Huan,GAO Yuan,JIANG Linlin.The morphological characteristics of bone marrow metastasis of common tumors in children［J］.Laboratory Medicine,2019,34(08):701-703.
[6] 张淑萍,沈乐园,宋一玲,等.ECT骨显像和骨髓涂片在神经母细胞瘤骨转移中的临床应用［J］.现代肿瘤医学,2020,28(06):989-993. ZHANG Shuping,SHEN Leyuan,SONG Yiling,et al.Clinical application of ECT bone imaging and bone marrow smear in bone metastasis of neuroblastoma ［J］.Modern Oncology,2020,28(06):989-993.
[7]ZHENG R,PENG X,ZENG H,et al.Incidence,mortality and survival of childhood cancer in China during 2000-2010 period:A population-based study［J］.Cancer Lett,2015,363(2):176-180.
[8] NAGAI J,ISHIDA Y,KOGA N,et al.A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry［J］.J Pediatr Hematol Oncol,2000,22(1):20-26.
[9] MATTHAY KK,REYNOLDS CP,SEEGER RC,et al.Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid:a children's oncology group study［J］.J Clin Oncol,2009,27(7):1007-1013.
[10] SCHENGRUND CL.Gangliosides and neuroblastomas［J］.Int J Mol Sci,2020,21(15):5313-5323.
[11] GEORGE RE,LI S,MEDEIROS-NANCARROW C,et al.High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation:long-term survival update［J］.J Clin Oncol,2006,24(18):2891-2896.
[12] PARK JR,KREISSMAN SG,LONDON WB,et al.Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma:A randomized clinical trial［J］.JAMA,2019,322(8):746-755.
[13] BOCHENNEK K,ESSER R,LEHRNBECHER T,et al.Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma［J］.Klin Padiatr,2012,224(3):139-142.
[14]李斯慧,聂晓璐,段超,等.神经母细胞瘤高危儿童筛查及其方案研究进展［J］.中国小儿血液与肿瘤杂志,2016,21(01):47-50. LI SH,NIE XL,DUAN C,et al.Progress in screening of high-risk children with neuroblastoma and its protocols［J］.Chinese Journal of Pediatric Hematology and Cancer,2016,21(01):47-50.
[15] YAN P,QI F,BIAN L,et al.Comparison of incidence and outcomes of neuroblastoma in children,adolescents,and adults in the United States:A surveillance,epidemiology,and end results(SEER) program population study［J］.Med Sci Monit,2020,26:e927218-1-e927218-13.
[16] KUBOTA M.The role of surgery in the treatment of neuroblastoma［J］.Surg Today,2010,40(6):526-532.
[17]彭雄文,沈乐园,王维达,等.通过血象变化判断神经母细胞瘤患者骨髓累及情况［J］.医学研究杂志,2018,47(10):129-134. PENG XW,SHEN LY,WANG WD,et al.Judging the bone marrow involvement of patients with neuroblastoma by changes in blood picture［J］.Journal of Medical Research,2018,47(10):129-134.
[18] UEMURA S,LIN KS,MON TK,et al.Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients［J］.Mol Clin Oncol,2021,15(1):137-148.
[19] ZHU CG,HE XL,TANG ZG,et al.Clinical features of neuroblastoma:an analysis of 44 children［J］.Chinese Journal of Contemporary Pediatrics,2020,22(11):1193-1197.
[20] RAIELI S,DI RENZO D,LAMPIS S,et al.MYCN drives a tumor immunosuppressive environment which impacts survival in neuroblastoma［J］.Front Oncol,2021,11:625207-625220.
[21] UEMURA S,ISHIDA T,THWIN K,et al.Dynamics of minimal residual disease in neuroblastoma patients［J］.Front Oncol,2019,9:455-468.
[22]倪燕.基于GD2免疫细胞学的微小病灶检测在高危神经母细胞瘤中的临床意义［D］.天津：天津医科大学,2019:678-686. NI Yan.Clinical significance of detection of small lesions in high-risk neuroblastoma based on GD2 immunocytology［D］.Tianjin：Tianjin Medical University,2019:678-686.

Memo

Memo:
-
Last Update: 2022-01-27